Yifan Zhao

Dr. Yifan Zhao

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
RLRuiyuan Li
Ruiyuan Li
AAAili Atawula
Aili Atawula
HLHaonan Li
Haonan Li
MLMoran Li
Moran Li
JTJiamin Tang
Jiamin Tang
LGLipeng Guo
Lipeng Guo
This study aims to investigate novel inflammatory markers, including the systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and aggregate inflammatory score index (AISI), and their relationship with coronary heart disease (CHD) in patients with hypertension (HT) using data from the National Health and Nutrition Examination Survey (NHANES). We conducted a cross-sectional study using complete data from the 2005–2016 NHANES survey. A total of 9,242 hypertensive participants aged 18 years or older were included in the study. Participants were divided into HT group and HT combined with CHD group. SII was calculated as PC × NC/LC, SIRI was calculated as NC × MC/LC, and AISI was calculated as MC × PC × NC/LC. Additionally, demographic, lifestyle factors and health-related information was gathered. Logistic regression models were utilized to pinpoint SII, SIRI, and AISI associated with HT combined with CHD, and constructed three nomogram models to forecast HT combined with CHD risk. In our cohort of 9,242 patients, 2,055 (30.77%) had CHD. Higher levels of log2-SII (OR 1.10, 95%CI: 1.03–1.17, P = 0.003), log2-SIRI (OR 1.27, 95%CI: 1.19–1.35, P < 0.001) and log2-AISI (OR 1.13, 95%CI: 1.07–1.19, P < 0.001) were associated with an increased likelihood of CHD in hypertensive patients. Elevated log2-SII, log2-SIRI, and log2-AISI, along with male gender, older age, non-Mexican American ethnicity, family poverty income ratio (PIR) < 1.5, and smoking, were identified as risk factors for CHD in hypertensive populations. Calibration curves were constructed to assess the deviation between predicted and actual values, with 1,000 bootstrap iterations showing good consistency between predictions and observed outcomes. AUC values of the three models were 0.724 (95% CI: 0.712–0.736), 0.730 (95% CI: 0.718–0.741), and 0.726 (95% CI: 0.714–0.737), respectively. All the three models had good discrimination power. Decision curve analysis indicated that all three nomogram models are effective in clinical practice. These novel immune-inflammatory markers (SII, AISI, SIRI) offer a simple, non-invasive, and cost-effective screening tool with promising clinical application for predicting CHD risk in HT population. They have the potential to guide personalized treatment, aligning with the goals of precision medicine.

18 October 2024 in JACC: Advances
Verified
Journal Article
Open access
MLMoran Li
Moran Li
SZSong Zhao
Song Zhao
SYShikai Yu
Shikai Yu
RMRusitanmujiang Maimaitiaili
Rusitanmujiang Maimaitiaili
YXYawei Xu
Yawei Xu
yi zhangyi zhang
yi zhang
There is no consensus on optimal time points or systolic blood pressure (SBP) ranges for calculating SBP time in target range (TTR). The purpose of this study was to examine the association between various SBP TTR metrics and long-term major adverse cardiovascular events (MACEs). This post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial) included participants with complete SBP records and excluded those with events in the initial 2 years. SBP TTR indices were calculated using 3 distinct time points and 3 SBP ranges. The SBP TTR index was the percentage of BP segments within the target SBP ranges. MACE, a composite of heart attack, stroke, heart failure, and cardiovascular death, was the primary outcome. The study included 7,134 participants, of which 280 had a MACE. The median follow-up was 3.91 years. The SBP TTR 110-140 mm Hg in the initial 3 months (3-month TTR 110-140) had the optimal association with incident MACEs (HR per SD increase: 0.898 [95% CI: 0.788-1.022], relative informativeness = 24,398%). Furthermore, a cutoff value of 0.65 for 3-month TTR 110 to 140 index was identified by threshold saturation analysis and used to evaluate early SBP control. No difference in MACE was seen between different mean SBP subgroups in those with good early control (3-month TTR >0.65) (P = 0.88), but in those with poor early control (3-month TTR ≤0.65), a higher mean SBP of 130 to 140 mm Hg was related to increased MACEs risk (P = 0.019). In nondiabetic hypertensive patients, the 3-month TTR 110 to 140 mm Hg index was independently associated with 2-year MACEs. A cutoff of TTR index as 0.65 indicated that the patient was within BP target range 65% of the time, combined with mean SBP, could potentially be used as a metric for early control stability and late cardiovascular risks. (Systolic Blood Pressure Intervention Trial [SPRINT]; NCT01206062)

Verified
Journal Article
Open access
PDF file
CXChong Xu
Chong Xu
MLMoran Li
Moran Li
WMWeilun Meng
Weilun Meng
JHJun Han
Jun Han
SZSong Zhao
Song Zhao
yi zhangyi zhang
yi zhang
With the epidemic of risk factors such as unhealthy lifestyle, obesity and mental stress, the prevalence of hypertension continues to rise across the world. Although standardized treatment protocols simplify the selection of antihypertensive drugs and ensure therapeutic efficacy, the pathophysiological state of some patients remains, which may also lead to the development of other cardiovascular diseases. Thus, there is an urgent need to consider the pathogenesis and selection of antihypertensive drug for different type of hypertensive patients in the era of precision medicine. We proposed the REASOH classification, based on the etiology of hypertension, including renin-dependent hypertension, elderly-arteriosclerosis-based hypertension, sympathetic-active hypertension, secondary hypertension, salt-sensitive hypertension and hyperhomocysteinemia hypertension. The aim of this paper is to propose a hypothesis and provide a brief reference for the personalized treatment of hypertensive patients.

26 January 2025 in ESC Heart Failure
Verified
Journal Article
Open access
LHLi Haonan
Li Haonan
HQHe Qiaorui
He Qiaorui
ZWZhu Wenqing
Zhu Wenqing
ZYZhang Yanjun
Zhang Yanjun
PWPingcuo Wangjia
Pingcuo Wangjia
YZYifan Zhao
Yifan Zhao
Aims: We aim to elucidate the association of baseline eGFR and incident heart failure on patients receiving intensive BP treatment. Methods and results: A post hoc analysis was conducted on the SPRINT database. Multivariab le Cox regression and interaction restricted cubic spline (RCS) analysis were performed to investigate the interaction between baseline eGFR and intensive BP control on heart failure prevention. The primary endpoint focused on incident heart failure. The study cohort comprised 8369 adults with a mean [SD] age of 68 [59–77] years, including 2940 women (35.1%). Over a median [IQR] follow-up period of 3.9 [2.0–5.0] years, 183 heart failure events were recorded. A significant interaction was observed between baseline eGFR and treatment groups in terms of heart failure prevention (Interaction P = 0.012). The risk of heart failure showed a sharp slope until eGFR = 75 mL/min/1.73 m2 and then became flat by an interaction RCS. Intensive BP treatment did not exhibit a preventive effect on heart failure (HR (95% CI) = 1.03 (0.82–1.52)) when baseline eGFR was 75 mL/min/1.73 m2 or lower. Conversely, when baseline eGFR was higher than 75 mL/min/1.73 m2, a reduced risk of heart failure was observed (HR (95% CI) = 0.65 (0.41–0.98)). Intensive BP control did not increase the incident long-term dialysis regardless of baseline eGFR but was associated with a higher risk of eGFR reduction. Conclusions: Among nondiabetic hypertensive patients, baseline eGFR serves as a crucial indicator for assessing the risk reduction potential of intensive BP control in heart failure prevention, with 75 mL/min/1.73 m2 appearing as a suitable cut-off value.

30 June 2025 in BMJ Digital Health & AI
Verified
Journal Article
Open access
PDF file
QHQiaorui He
Qiaorui He
YHYang Hou
Yang Hou
XXXiao Xu
Xiao Xu
JLJinlei Li
Jinlei Li
XZXianxian Zhao
Xianxian Zhao
YZYifan Zhao
Yifan Zhao
Objective: The inaccurate identification of the culprit vessel is a critical issue in the treatment of patients with ST-segment elevated myocardial infarction (STEMI). This study aimed to establish an artificial intelligence (AI)-based algorithm for the culprit vessel identification in patients with STEMI. Methods and analysis: 698 ECGs were conducted within 12 hours before primary percutaneous coronary intervention from patients with STEMI. The internal training and testing sets consisted of 543 ECGs collected from two tertiary hospitals, and the external validation set consisted of 155 ECGs collected from another independent tertiary hospital. These ECGs represented STEMI patients with various culprit vessels, such as left anterior descending artery (LAD), right coronary artery (RCA) and left circumflex artery (LCX), validated by further coronary angiography (CAG). Results: Among 698 patients (mean (SD) age, 71.1 (11.3) years), the culprit vessels were LAD in 328, RCA in 288 and LCX in 82. In the internal training, an algorithm was developed (LAD: sensitivity 92.4%, specificity 99.7%; RCA: sensitivity 93.2%, specificity 97.4%; LCX: sensitivity 99.7%, specificity 95.8%). Internal testing revealed that it achieved high performance metrics (LAD: sensitivity 91.6%, specificity 96.0%; RCA: sensitivity 75.1%, specificity 95.8%; LCX: sensitivity 97.0%, specificity 88.8%), outperforming cardiologists and commercial algorithm. In the external validation, it also demonstrated competitive performance (LAD: sensitivity 72.0%, specificity 94.3%; RCA: sensitivity 90.5%, specificity 92.4%; LCX: sensitivity 92.9%, specificity 91.2%). Conclusion: We established and validated an AI-based algorithm for the culprit vessel identification in patients with STEMI, comparable to experienced cardiologists. The generalisability of our algorithm on a global scale needs further verification. Trial registration number: NCT03317691.

6 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
JHJun Han
Jun Han
JTJiaMin Tang
JiaMin Tang
YZYifan Zhao
Yifan Zhao
JXJing Xiong
Jing Xiong
SZSong Zhao
Song Zhao
NSNorthern Shanghai Study
Northern Shanghai Study
Background: The subendocardial viability ratio (SEVR) reflects myocardial perfusion relative to workload. This study explored the association of SEVR with mortality and subclinical target organ damage in an older adult population. Methods: We analyzed the data from the Northern Shanghai Study, a community‐based cohort of older adults aged over 65 years. SEVR was measured with arterial tonometry. Cross‐sectional associations were assessed between SEVR levels and target organ damage (including arterial stiffness, peripheral artery disease, carotid plaque, left ventricular hypertrophy, left ventricular diastolic dysfunction, chronic kidney dysfunction, and microalbuminuria). Longitudinal associations between SEVR and mortality were evaluated using Cox and Fine‐Gray models. Results: Among 3237 participants (mean age 71±6 years, 57% female), 233 deaths occurred over a median follow‐up of 5.7 years, including 94 cardiovascular deaths. Participants were divided into 2 groups by the median value of SEVR (129%). The group with a lower SEVR (≤129%) was associated with higher risk of cardiovascular death (adjusted Cox Hazard Ratio [HR]=1.70 [1.05–2.75]; P =0.03), but not with all‐cause death (adjusted Cox HR=1.30 [0.98–1.73]; P =0.07). As for target organ damage, participants with more damaged organs had lower SEVR values ( P for trend <0.001). Specifically, the occurrence of arterial stiffness and left ventricular diastolic dysfunction increased the potential of worse SEVR, with odds ratio 1.46 (1.17–1.83); P <0.001, and 1.90 (1.35–2.67); P <0.001, respectively. Conclusions: Lower SEVR is independently associated with both increased cardiovascular mortality and organ damage, including arterial stiffness and left ventricular diastolic dysfunction in older adult populations. SEVR may be a convenient marker for early cardiovascular risk stratification in aging populations. Registration: URL: https://ClinicalTrial.gov ; Unique Identifier: NCT02368938.